New drug combo shows promise for Tough-to-Treat head and neck cancer
NCT ID NCT04313504
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, niraparib and dostarlimab, in 10 people with head and neck cancer that had come back or spread. The goal was to see if the combination could shrink tumors or slow the cancer. Participants had to be able to swallow pills and have no other curative options. The study is complete, and results help guide future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tailored nutrition boost recovery from head and neck surgery?
- Can less radiation be safer for throat cancer?
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new drug boost the power of chemoradiation against head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?